Cytokinetics will present a corporate update at the Stifel Cardiometabolic Forum on September 30, 2025.
Quiver AI Summary
Cytokinetics, Incorporated announced that its management team will present a corporate update during the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 10:00 AM Eastern Time, with a live webcast available on their website. The company specializes in cardiovascular biopharmaceuticals and is advancing innovative treatments for cardiac muscle dysfunction, including aficamten, a cardiac myosin inhibitor, which has shown positive Phase 3 trial results for treating obstructive hypertrophic cardiomyopathy. Cytokinetics is also developing other therapies, such as omecamtiv mecarbil for heart failure, ulacamten for heart failure with preserved ejection fraction, and CK-089 for skeletal muscle conditions. The press release includes forward-looking statements but cautions that actual results may differ due to various risks.
Potential Positives
- Cytokinetics is preparing for potential regulatory approvals and commercialization of aficamten, following positive results from the pivotal Phase 3 clinical trial SEQUOIA-HCM, indicating strong progress in their product pipeline.
- The company's participation in the Stifel 2025 Virtual Cardiometabolic Forum presents an opportunity to enhance visibility among investors and stakeholders, potentially attracting interest in its ongoing developments.
- Cytokinetics is advancing multiple product candidates, including innovative therapies targeting various forms of heart failure and muscular dystrophy, showcasing a diversified and potentially impactful pipeline.
Potential Negatives
- The press release highlights the reliance on forward-looking statements, indicating uncertainty about future performance and potential risks affecting the company's operations and financial condition.
- Cytokinetics emphasizes various risks and uncertainties that may cause actual results to differ materially from their expectations, which could undermine investor confidence.
- The disclaimer regarding the obligation to update forward-looking statements may lead to perceptions of a lack of transparency and accountability to stakeholders.
FAQ
What is Cytokinetics announcing in the press release?
Cytokinetics is presenting a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025.
How can I access the Cytokinetics webcast?
The live webcast can be accessed via the Investors & Media section of the Cytokinetics website.
How long will the webcast replay be available?
The replay of the webcast will be archived for 90 days after the event concludes.
What diseases is Cytokinetics focusing on?
Cytokinetics is developing treatments for diseases related to cardiac muscle dysfunction and skeletal muscle conditions.
Who should I contact for more information about Cytokinetics?
For more information, contact Diane Weiser, Senior Vice President of Corporate Affairs at Cytokinetics.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CYTK Congressional Stock Trading
Members of Congress have traded $CYTK stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/11 and 1 sale worth up to $15,000 on 06/17.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$CYTK Insider Trading Activity
$CYTK insiders have traded $CYTK stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $CYTK stock by insiders over the last 6 months:
- ROBERT I BLUM (President & CEO) has made 0 purchases and 12 sales selling 70,000 shares for an estimated $2,705,150.
- FADY IBRAHAM MALIK (EVP Research & Development) has made 0 purchases and 11 sales selling 22,000 shares for an estimated $806,480.
- WENDALL WIERENGA sold 20,000 shares for an estimated $769,200
- ANDREW CALLOS (EVP, Chief Commercial Officer) has made 0 purchases and 3 sales selling 15,547 shares for an estimated $527,488.
- EDWARD M. MD KAYE has made 0 purchases and 2 sales selling 10,392 shares for an estimated $454,515.
- JOHN T HENDERSON sold 3,190 shares for an estimated $123,325
- ROBERT ARTHUR HARRINGTON has made 0 purchases and 2 sales selling 2,600 shares for an estimated $122,384.
- MUNA BHANJI sold 1,454 shares for an estimated $43,227
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CYTK Hedge Fund Activity
We have seen 170 institutional investors add shares of $CYTK stock to their portfolio, and 212 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 7,647,189 shares (+76.8%) to their portfolio in Q2 2025, for an estimated $252,663,124
- MARSHALL WACE, LLP removed 2,007,567 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $66,330,013
- POINT72 ASSET MANAGEMENT, L.P. removed 1,722,984 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $56,927,391
- WESTFIELD CAPITAL MANAGEMENT CO LP removed 1,310,336 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $43,293,501
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 1,256,580 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $41,517,403
- DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,160,315 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $38,336,807
- JANUS HENDERSON GROUP PLC removed 1,007,582 shares (-95.3%) from their portfolio in Q2 2025, for an estimated $33,290,509
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CYTK Analyst Ratings
Wall Street analysts have issued reports on $CYTK in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/22/2025
- JMP Securities issued a "Market Outperform" rating on 09/02/2025
- Citigroup issued a "Buy" rating on 09/02/2025
- Needham issued a "Buy" rating on 09/02/2025
- Stifel issued a "Buy" rating on 09/02/2025
- JP Morgan issued a "Overweight" rating on 06/09/2025
- Mizuho issued a "Outperform" rating on 05/29/2025
To track analyst ratings and price targets for $CYTK, check out Quiver Quantitative's $CYTK forecast page.
$CYTK Price Targets
Multiple analysts have issued price targets for $CYTK recently. We have seen 15 analysts offer price targets for $CYTK in the last 6 months, with a median target of $78.0.
Here are some recent targets:
- Mayank Mamtani from B. Riley Securities set a target price of $80.0 on 09/22/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $120.0 on 09/22/2025
- Cory Kasimov from Evercore ISI Group set a target price of $80.0 on 09/03/2025
- Gena Wang from Barclays set a target price of $71.0 on 09/03/2025
- David Lebowitz from Citigroup set a target price of $84.0 on 09/02/2025
- Jason N. Butler from JMP Securities set a target price of $78.0 on 09/02/2025
- James Condulis from Stifel set a target price of $96.0 on 09/02/2025
Full Release
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to present a corporate update at the Stifel 2025 Virtual Cardiometabolic Forum on Tuesday, September 30, 2025 at 10:00 AM Eastern Time.
Interested parties may access the live webcast of the fireside chat by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com . The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil , a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten , a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X , LinkedIn , Facebook and YouTube .
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
